DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Household
Published
18 Jul 24
Updated
04 Aug 26
Views
696
Not Invested
Colgate-PalmoliveCL
CL logo
Fair Value
US$98.95
Share price04 Aug
US$88.0311.0% undervalued intrinsic discount
Loading
1Y5.81%
7D-2.30%

CL: Future Cost Optimization Will Drive Competitive Advantage Amid Category Headwinds

AN
AnalystConsensusTarget
AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
18 Jul 24
Updated
04 Aug 26
Views
696
Not Invested
Fair ValueUS$98.95
Share priceUS$88.03
11.0% undervalued intrinsic discount
Narrative
Updates22

Last Update 04 Aug 26

Fair value Increased 2.34%

CL: International Execution And Pet Nutrition Will Offset 2026 Margin Pressures

Analysts have nudged their fair value estimate for Colgate-Palmolive higher from about $96.68 to roughly $98.95. This reflects updated price targets that highlight solid profit execution, resilient international growth and model tweaks after recent quarterly results.

Analyst Commentary

Recent Street research on Colgate-Palmolive centers on how solid profit execution and resilient international growth stack up against more muted readings in the U.S. and valuation that some see as already reflecting a fair share of the story.

Bullish Takeaways

  • Bullish analysts point to consistent international growth as a key driver of Colgate-Palmolive’s earnings profile, with several reports highlighting strong momentum outside the U.S. as a support for current and higher valuation targets.
  • Some see room for further upside in pet nutrition, where they expect Colgate-Palmolive to keep gaining shelf space and share by adding value through differentiated products, even in a flat or slightly weaker category.
  • Several firms raised price targets into a US$100 to US$110 range, reflecting confidence that profit execution, including better-than-expected gross margins tied to productivity and one-off benefits such as tariff refunds, supports higher fair value assumptions.
  • JPMorgan and other bullish analysts continue to rate the stock positively, citing ongoing international growth and signs of sequentially better consumption together with less severe commodities pressure as supportive for earnings resilience.

Bearish Takeaways

  • Some cautious analysts emphasize that Colgate-Palmolive’s organic sales growth is described as slightly below certain global household and personal care peers, which they see as limiting scope for a higher valuation multiple at current levels.
  • Concerns around the U.S. business remain a focus, with the split between strong international results and softer North America performance likely to keep attention on whether domestic growth can improve in the coming quarters.
  • One firm initiated coverage at a neutral rating with a US$96 price target, indicating that the current share price already captures much of the expected upside and that valuation rather than business quality is the main constraint.
  • Some commentary references expectations for muted trends in the U.S. and Europe, which could cap revenue momentum and keep investors cautious about paying a premium P/E multiple until growth in these regions becomes clearer.

What’s in the News for Colgate-Palmolive

  • Colgate-Palmolive reported Q2 2026 net sales of US$5.4b, which the company said was 4.9% higher year over year, supported by continued international momentum and contributions from emerging markets and pet nutrition. Source: Company earnings release.
  • Management guided for full year 2026 net sales growth of 2% to 6% and organic sales growth of 1% to 4%, with a low single digit positive impact expected from foreign exchange. Source: Company earnings release and guidance update.
  • The company highlighted around US$300m of extra raw material and logistics costs in 2026 and lowered its full year gross margin outlook as a result, while keeping full year net sales and EPS guidance unchanged. Source: Company earnings release.
  • Colgate-Palmolive said it still expects double digit GAAP EPS growth and mid single digit adjusted EPS growth for 2026, with currency movements and North American market conditions flagged as key risks. Source: Company earnings release.
  • Investors were invited to a live webcast of the Q2 2026 earnings call on July 31, 2026, featuring CEO Noel Wallace and senior executives, to discuss results and the 2026 outlook. Source: Company earnings release.

Valuation Changes

  • Fair value has risen slightly from about $96.68 to roughly $98.95, which reflects a modest uplift in the assessed worth of Colgate-Palmolive shares.
  • The discount rate is fractionally higher at 7.11% compared with 6.98%, indicating a slightly greater required return in the updated model.
  • The revenue growth assumption has eased from about 3.76% to roughly 3.16%, which points to a more cautious view on future dollar sales expansion.
  • The net profit margin forecast has been trimmed from around 15.47% to about 14.80%, implying a slightly softer dollar earnings profile relative to earlier expectations.
  • The future P/E has moved up from roughly 26.1x to about 27.2x, which signals a higher valuation multiple being applied to Colgate-Palmolive in the new framework.
Read more
4 viewsusers have viewed this narrative update

Key Takeaways

  • Expansion in oral care and focus on emerging markets, with premiumization and innovation, drive sustained volume growth and strengthen global brand positioning.
  • Investment in AI, digital transformation, and productivity boosts efficiencies, enabling reinvestment into growth and supporting stable margins and resilience against market cycles.
  • Persistent cost pressures, cautious consumer behavior, and competitive challenges in major markets are constraining margin expansion, topline growth, and long-term revenue prospects.

Catalysts

About Colgate-Palmolive
    Manufactures and sells consumer products in the United States and internationally.
What are the underlying business or industry changes driving this perspective?
  • Expansion and premiumization of core oral care lines like Colgate Total, coupled with the roll-out of complementary products across 75 markets, are set to capture increased value from emerging middle-class consumers and rising health/hygiene awareness globally-supporting top-line organic sales acceleration and improved pricing power.
  • Emerging markets such as India, Latin America, and Southeast Asia-where rising incomes and urbanization are growing the addressable customer base-remain a strategic focus with stepped-up innovation, brand investment, and price tiering, sustaining long-term volume and revenue growth.
  • Continued investments in AI, digital transformation, and omnichannel demand generation are expected to enhance operational efficiency, customer reach, and data-driven marketing, translating into greater sales effectiveness and margin resilience.
  • Productivity and restructuring initiatives ($200–$300 million over three years) are designed to free up resources for innovation, digital, and R&D investments, enabling incremental margin expansion and additional reinvestment for growth.
  • Category stabilization and long-term brand strength, particularly in daily-use, trusted segments (oral care, pet nutrition), position Colgate-Palmolive to outperform peers as consumer confidence rebounds, supporting consistent earnings growth and de-risking revenue from cyclical downturns.
Colgate-Palmolive Earnings and Revenue Growth

Colgate-Palmolive Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Colgate-Palmolive's revenue will grow by 3.2% annually over the next 3 years.
  • Analysts assume that profit margins will increase from 9.7% today to 14.8% in 3 years time.
  • Analysts expect earnings to reach $3.4 billion (and earnings per share of $4.39) by about August 2029, up from $2.0 billion today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $2.9 billion.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.2x on those 2029 earnings, down from 35.2x today. This future PE is greater than the current PE for the US Household Products industry at 20.9x.
  • Analysts expect the number of shares outstanding to decline by 1.37% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  • Consumer caution and category softness in key markets like North America, Brazil, and India could persist due to elevated food inflation and macroeconomic uncertainty, potentially constraining volume growth and revenue.
  • Rising raw material and packaging costs, particularly for palm oil and fats, are significantly impacting gross margin, and relief is uncertain, posing ongoing pressure on net margins and profitability.
  • Increased focus on price pack architecture and value offerings in response to cautious consumers and lower category inflation may limit the company's ability to drive premium pricing, potentially compressing margins and slowing topline growth.
  • Company performance in China and India is being challenged by local market dynamics, with China's Hawley & Hazel business requiring significant repositioning in a highly competitive e-commerce environment and India experiencing urban market sluggishness, both of which could hinder long-term revenue growth in these important markets.
  • Continued exposure to private label competition, especially in the pet food category and key emerging markets, along with the exit from private label production, could negatively impact reported sales growth and overall earnings during the transition period.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $98.95 for Colgate-Palmolive based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $87.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $23.1 billion, earnings will come to $3.4 billion, and it would be trading on a PE ratio of 27.2x, assuming you use a discount rate of 7.1%.
  • Given the current share price of $89.88, the analyst price target of $98.95 is 9.2% higher.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Colgate-Palmolive?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Comments

0 comments

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

CL logo
Colgate-Palmolive
1.8% overvalued intrinsic discount

The Ten Percent Margin Is A Write Down, Not The Business

View narrative
RC
Emerging Author
rcb9
Published 3 Aug
Read Narrative

Fair Value vs Share Price

US$98.95
vs US$88.0311.0% undervalued intrinsic discount
PastFuture023b2015201820212024202620272029Revenue US$23.1bEarnings US$3.4b
3.2%
Revenue growth
14.8%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Colgate-Palmolive

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Established dividend payer with mediocre balance sheet.

Market capUS$70.5b
PB297.4x
Estimated Growth3.1%
Dividend Yield2.4%
Full analysis

CEO & management

Noel Wallace
CEO
2.7yrs
CEO Tenure

Manufactures and sells consumer products in the United States and internationally.

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide